Arylnitro monocarbonyl curcumin analogues: Synthesis and in vitro antitubercular evaluation

Chem Biol Drug Des. 2023 Mar;101(3):717-726. doi: 10.1111/cbdd.14174. Epub 2022 Nov 17.

Abstract

Curcumin is a natural product that has been reported to exhibit myriad pharmacological properties, one of which is antitubercular activity. It demonstrates antitubercular activity by directly inhibiting Mycobacterium tuberculosis (M.tb) and also enhances immune responses that ultimately lead to the elimination of M.tb by macrophages. This natural product is, however, unstable, and several analogues, noticeably monocarbonyl analogues, have been synthesized to overcome this challenge. Curcumin and its monocarbonyl analogues reported so far exhibit moderate antitubercular activity in the range of 7 to 16 μM. Herein, we report a straightforward synthesis of novel monocarbonyl curcumin analogues, their antitubercular activity, and the structure-activity relationship. The hit compound from this study, 3a, exhibits potent MIC90 values in the range of 0.2 to 0.9 μM in both ADC and CAS media.

Keywords: analogues; aryl nitro; curcumin; synthesis; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Curcumin*
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis*
  • Structure-Activity Relationship

Substances

  • Curcumin
  • Antitubercular Agents